Anti-infectious activity of synbiotics in a novel mouse model of methicillin-resistant Staphylococcus aureus infection
Version of Record online: 23 APR 2010
© 2010 The Societies and Blackwell Publishing Asia Pty Ltd
Microbiology and Immunology
Volume 54, Issue 5, pages 265–275, May 2010
How to Cite
Lkhagvadorj, E., Nagata, S., Wada, M., Bian, L., Wang, C., Chiba, Y., Yamashiro, Y., Shimizu, T., Asahara, T. and Nomoto, K. (2010), Anti-infectious activity of synbiotics in a novel mouse model of methicillin-resistant Staphylococcus aureus infection. Microbiology and Immunology, 54: 265–275. doi: 10.1111/j.1348-0421.2010.00224.x
- Issue online: 23 APR 2010
- Version of Record online: 23 APR 2010
- Received 23 October 2009; revised 27 January 2010; accepted 9 February 2010.
- anti-infectious activity;
- Bifidobacterium breve;
- methicillin-resistant Staphylococcus aureus;
The anti-infectious activity of synbiotics against methicillin-resistant Staphylococcus aureus (MRSA) infection was evaluated using a novel lethal mouse model. Groups of 12 mice treated with multiple antibiotics were infected orally with a clinical isolate of MRSA at an inoculum of 108 CFU on day 7 after starting the antibiotics. A dose of 400 mg/kg 5-fluorouracil (5-FU) was injected intraperitoneally on day 7 after the infection. A dose of 108 CFU Bifidobacterium breve strain Yakult and 10 mg of galactooligosaccharides (GOS) were given orally to mice daily with the antibiotic treatment until day 28. The intestinal population levels of MRSA in the mice on multiple antibiotics were maintained stably at 108 CFU/g of intestinal contents after oral MRSA infection and the subsequent 5-FU treatment killed all the mice in the group within 14 days. B. breve administration saved most of the mice, but the synbiotic treatment saved all of the mice from lethal MRSA infection. The synbiotic treatment was effective for the treatment of intestinal infection caused by four MRSA strains with different toxin productions. There was a large difference among the six Bifidobacteria strains that were naturally resistant to the antibacterial drugs used. B. breve in combination with GOS is demonstrated to have valuable preventive and curative effects against even fatal MRSA infections.